Exelixis Expands Agreement With Bristol Myers For STELLAR-002 Trial - Quick Facts

(RTTNews) - Exelixis, Inc. (EXEL) announced the expansion of clinical trial collaboration and supply agreement with Bristol-Myers Squibb (BMY) to include the use of the fixed-dose combination of nivolumab and relatlimab in the phase 1b STELLAR-002 trial, which is evaluating XL092 in combination with multiple immune checkpoint inhibitors in advanced solid tumors. Bristol Myers Squibb will provide the fixed-dose combination of nivolumab and relatlimab in addition to nivolumab and ipilimumab for use in the trial.

Vicki Goodman, Chief Medical Officer, Exelixis, said: "By studying multiple immune checkpoint combinations, we hope to identify the most promising regimens across multiple solid tumors to use in future pivotal trials."

For More Such Health News, visit rttnews.com.